News | May 18, 2026
Alembic Pharmaceuticals posts strong Q4 FY26 growth as net profit jumps 29%
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Company enters women’s personal grooming segment while strengthening pain management portfolio with herbal Ortho Oil
30,000 sq. ft. multispeciality facility aims to deliver integrated care for women across every life stage
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
The Ibuprofen business posted a negative EBITDA of Rs. 179 million in Q4 despite revenue rising 61% year-on-year to Rs. 849 million
Medanta expanded its bed capacity by 20% during the year
The move signals a strategic pivot toward deeper integration between clinical leadership and medical technology developers
The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters
The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
Subscribe To Our Newsletter & Stay Updated
